MDSL
JAZZ icon

M.D. Sass LLC’s Jazz Pharmaceuticals JAZZ Stock Holding History

M.D. Sass LLC’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-162,666
Closed -$25.3M – 31
2022
Q1 		$25.3M Buy
162,666
+30,657
+23% +$4.45M 4.33% 12
2021
Q4 		$16.8M Buy
+132,009
New +$17.3M 2.61% 19

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

M.D. Sass LLC's JAZZ Position: Q2 2022 in Review

M.D. Sass LLC sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2022, closing a stake of 162,666 shares — an estimated $25.3M sold.

M.D. Sass LLC first reported a position in JAZZ in Q4 2021 and held it in 2 quarters. The position peaked at $25.3M in Q1 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q2 2022.

  • M.D. Sass LLC reported no remaining Jazz Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • M.D. Sass LLC sold 162,666 Jazz Pharmaceuticals shares in Q2 2022, an estimated $25.3M.
  • M.D. Sass LLC first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • M.D. Sass LLC's Jazz Pharmaceuticals position peaked at $25.3M in Q1 2022.
  • 468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2022.

Based on M.D. Sass LLC's 13F filing for Q2 2022, filed 15 Aug 2022.